Why the study?
Does permanent pacemaker treatment affect morbidity and mortality in patients over 75 years old compared to the general population?
Does permanent pacemaker treatment affect morbidity and mortality in patients over 75 years old compared to the general population?
Permanent pacemaker implantation in patients over 75 is a safe, symptom-relieving procedure with a long-term prognosis similar to the general matched population after the first year.
Answers are grounded in this paper and cite their sources.
Early excess mortality post-pacemaker in patients >75 warrants close initial monitoring; leaves open long-term survival equivalence versus matched controls.
Of 693 patients on permanent pacemaker treatment between 1962 and 1981, 282 (40.7%) were above the age of 75. Of this number, 142 patients were 75-79 years, 95 80-84 years and 45 85-93 (mean 87) years old at the time of the first pacemaker implantation. The patients were followed for 13-154 months (mean 37.1) with special attention being paid to morbidity and mortality after the implantation. Complications occurred in 65 (23%) of the elderly patients, with no significant difference between the three age groups. Excessive threshold rise with stimulation failure (6%) and infections or skin erosions (4.9%) were the most frequent complications. Mortality increased in all age groups during the first 6-12 months compared with the age- and sex-matched Norwegian population. Five-year survival rates were 56, 32 and 25% respectively. We conclude that cardiac pacemaker treatment in the elderly is a safe symptom-relieving therapeutic procedure and that the prognosis for these patients is similar to that for their fellow senior citizens after the first year of treatment.
No takes yet. Share an insight, caveat, or question.
BREIVIK et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: